Our website uses its own and third parties cookies for a high level of user-friendliness. If you continue to browse and  use this website we will assume that you agree with the policies.

R&D

3TR. Taxonomy, Treatment, Targets and Remission: Identification of the Molecular Mechanisms of non-response to Treatments, relapses and remission in Autoimmune Inflammatory Conditions

Despite the wide availability of treatments for autoimmune, inflammatory and allergic diseases, the response to therapy and the disease progression is unpredictable and varies from patient to patient.

3TR is a transdisciplinary Consortium that proposes multi-dimensional molecular analysis of multiple sample types collected longitudinally from homogeneously recruited patient cohorts suffering from seven different autoimmune diseases. The major aim of 3TR is that through a new Taxonomy, new mechanisms of Treatment unresponsiveness will drive the identification of new therapeutic Targets to improve unstained remission in patients with autoimmune inflammatory diseases. We propose that this high-resolution multi-omics analysis of individualized disease trajectories will facilitate stratification and identification of molecular patterns that better predict response to therapy and identify patients likely to relapse/flare or enter remission.

This new project is funded by the Innovative Medicine Initiative, a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA) which provides funding for health research and innovation.

Kick off: september 2019